1228 — CANbridge Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- HK$1.14bn
- HK$1.08bn
- CNY49.98m
Brief: CANbridge Pharmaceuticals Posts HY Loss of RMB37.1 MLN
Brief: Canbridge Pharmaceuticals Says Livmarli Obtains NHIA Reimbursement Approval In Taiwan For ALGS And PFIC
Brief: Canbridge Pharmaceuticals Initiates Registration And Launch Preparations For Gaurunning In North African Market
CANbridge Pharmaceuticals jumps as WuXi Biologics buys shares
Brief: Canbridge Pharmaceuticals Inc To Issue Aggregate Of 84 Million Subscription Shares
Brief: Canbridge Pharmaceuticals Announces CAN 103 Included In China's Innovative Drug List
Brief: CANbridge Pharmaceuticals Inc To Issue 10 Million Shares At HK$2.26 Per Share
Brief: Canbridge Pharmaceuticals Announces Units Formalized Strategic Relationship
Brief: CANbridge Pharmaceuticals Inc To Issue 75 Million Subscription Shares At HK$1.34 Per Share
Brief: Canbridge Pharmaceuticals Says Velaglucerase-Beta Injection Approved In China
Brief: Canbridge Pharmaceuticals Says Grant Of Priority Review Status Of CAN103
Brief: Canbridge Pharmaceuticals Says Glenn Hassan Has Tendered His Resignation As Chief Financial Officer
Brief: CANbridge Pharmaceuticals Posts H1 Revenue RMB 44.8 Mln
Brief: Canbridge Pharmaceuticals Says HY Revenue Increased 24.2% To RMB43.1 Million
Brief: CANbridge To Continue CAN008 Phase 2 Trial In Glioblastoma Multiforme In China Based On Interim Analysis Of Independent Data Monitoring Committee
Brief: Canbridge Pharmaceuticals Says Granted Marketing Approval By NMPA For Livmarli
Brief: Canbridge Pharmaceuticals Posts FY Loss Attributable RMB483.5 Million
Over a dozen Chinese-based firms say they have minimal exposure to SVB (updated)
Brief: Canbridge Says Consolidates Gene Therapy Portfolio